Trial Profile
A retrospective, multicentre study assessing safety and efficacy of Brentuximab Vedotin in patients with recurrent Hodgkin lymphoma after allogeneic stem cell transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2019
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms LWP-EBMT
- 06 Nov 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 31 Oct 2018 New trial record
- 23 Oct 2018 Results published in the Cancer